Katarína Rejleková

ORCID: 0000-0002-2142-3411
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Testicular diseases and treatments
  • Neuroblastoma Research and Treatments
  • Sarcoma Diagnosis and Treatment
  • Bladder and Urothelial Cancer Treatments
  • Glioma Diagnosis and Treatment
  • Inflammatory Biomarkers in Disease Prognosis
  • Cancer Immunotherapy and Biomarkers
  • Immune Cell Function and Interaction
  • Multiple Myeloma Research and Treatments
  • Renal cell carcinoma treatment
  • Histone Deacetylase Inhibitors Research
  • Cancer-related cognitive impairment studies
  • Cancer Treatment and Pharmacology
  • Cancer Genomics and Diagnostics
  • Neutropenia and Cancer Infections
  • Hematological disorders and diagnostics
  • Cardiac tumors and thrombi
  • Adrenal and Paraganglionic Tumors
  • Multiple and Secondary Primary Cancers
  • Gestational Trophoblastic Disease Studies
  • Venous Thromboembolism Diagnosis and Management
  • Ovarian cancer diagnosis and treatment
  • Lung Cancer Research Studies
  • Chemotherapy-induced organ toxicity mitigation
  • Cancer, Hypoxia, and Metabolism

Comenius University Bratislava
2016-2025

Cancer Institute (WIA)
2017-2023

Slovak Medical University
2015-2023

National Institute of Cardiovascular Diseases
2022

National Cancer Institute
2015-2021

Vysoká Škola Zdravotníctva a Sociálnej Práce sv. Alžbety
2020

Národný Onkologický Ústav
2018-2020

642 Background: Salvage chemotherapy for relapsed testicular germ cell tumors (GCT) remains controversial, however, large retrospective series show higher cure rates with high-dose (HDCT) and peripheral blood stem transplant (PBSCT) compared to conventional dose (CDCT). Successful implementation of HDCT salvage treatment in high-volume centers is an important step towards achieving optimal GCTs. Methods: 22 GCT patients were treated at National Cancer Institute Slovakia first (41%), second...

10.1200/jco.2025.43.5_suppl.642 article EN Journal of Clinical Oncology 2025-02-10

We evaluated systemic immune-inflammation index (SII) and its association with patient outcome in germ-cell tumours (GCTs).Two independent cohorts of patients were analysed; the discovery set (n=171) from a single institution validation (n=181) previously included study evaluating PD-L1 GCTs. The SII was calculated using platelet (P), neutrophil (N) lymphocyte (L) counts before chemotherapy correlated survival regression analyses Kaplan-Meier method.In cohort, associated poor risk clinical...

10.1038/bjc.2017.460 article EN cc-by-nc-sa British Journal of Cancer 2018-02-27

// Michal Chovanec 1, 2, 7, * , Zuzana Cierna 3, Viera Miskovska 4 Katarina Machalekova 5 Daniela Svetlovska 6 Kalavska 8 Rejlekova 7 Stanislav Spanik Karol Kajo Pavel Babal 9 Jozef Mardiak Mego 1 2nd Department of Oncology, Comenius University, Faculty Medicine & National Cancer Institute, Bratislava, Slovak Republic 2 Translational Research Unit, 3 Pathology, Medicine, 1st St. Elisabeth Medical University Clinical Trials, Academy Sciences, Hospital with Policlinics Skalica, a.s., M-CH and...

10.18632/oncotarget.15585 article EN Oncotarget 2017-02-21

Background: Immunotherapy based on checkpoint inhibition is widely used in the treatment of metastatic renal cell carcinoma (RCC); however, predictive and prognostic biomarkers are yet to be explored. The objective this study was evaluate value hemoglobin, albumin, lymphocyte, platelet (HALP) score RCC patients receiving nivolumab. Methods: We enrolled 149 individuals (including 38 females) with a median age 62 years, who were treated nivolumab (at dosage 240 mg biweekly or 480 every 28...

10.3390/biomedicines13020484 article EN cc-by Biomedicines 2025-02-16

Abstract Background Treatment for cancer may lead to development of cognitive difficulties in survivors. This study aimed evaluate long-term functioning (CogF) germ-cell tumor (GCT) Subjects, Materials, and Methods GCT survivors (n = 155) from the National Cancer Institute Slovakia completed Functional Assessment Therapy Cognitive Function at a median 10 years follow-up (range: 5–32). The group consisted receiving cisplatin-based chemotherapy, radiotherapy retroperitoneal lymph nodes, or...

10.1634/theoncologist.2017-0457 article EN The Oncologist 2018-01-19

Germ cell tumours (GCTs) represent a highly curable malignity as they respond well to cisplatin (CDDP)-based chemotherapy. Nevertheless, small proportion of GCT patients relapse or do not therapy. As this might be caused by an increased capacity repair CDDP-induced DNA damage, identification biomarkers predicting inadequate aberrant response CDDP, and thus poor prognosis for patients, poses challenge. The objective study is examine the expression levels key nucleotide excision (NER) factors,...

10.1186/s12885-019-6496-1 article EN cc-by BMC Cancer 2020-01-06

Germ cell neoplasia in situ (GCNIS), is preinvasive stage of testicular germ tumours (TGCTs). Fibrillins, which are integral components microfibrils suggested to be involved cancer pathogenesis and maintenance embryonic stem cells pluripotency. The aim this study was examine fibrillin-1 (FBN-1) expression TGCTs patients.Surgical specimens from 203 patients with were included into the translational study. FBN-1 evaluated tumour tissue, GCNIS adjacent non-neoplastic tissue all available cases....

10.1186/s12885-016-2644-z article EN cc-by BMC Cancer 2016-08-04

WNT/βcatenin (WNTβ) pathway is activated in early stages of embryonic development. We aimed to evaluate the significance βcatenin germ cell tumors (GCTs) and explore associations with inflamed environment.Surgical specimens from 247 patients were analyzed. Βcatenin expression was detected tumor tissue by immunohistochemistry correlated clinical characteristics, outcome, PD-L1 systemic immune-inflammation index (SII). The Ingenuity Pathway Analysis (IPA) used investigate immune-cell related...

10.1186/s12885-018-4929-x article EN cc-by BMC Cancer 2018-11-03

Abstract Background Survivors of germ-cell tumors (GCT) may suffer from long-term adverse consequences. Our study was conducted to assess a sexual functioning in GCT survivors. Methods survivors ( N = 170) the National Cancer Institute Slovakia completed Sexual Function Questionnaire that modified PROMIS and Satisfaction 9-year median follow up (range 5–32) as primary exploratory aim. Study groups consisted 17 (10%) who had active surveillance (AS, controls), 153 (90%) received treatment...

10.1186/s12885-020-07301-6 article EN cc-by BMC Cancer 2020-08-20

// Zuzana Sestakova 1, * , Katarina Kalavska 2, Lenka Hurbanova 1 Dana Jurkovicova Jan Gursky Michal Chovanec 3, 4 Daniela Svetlovska 2 Vera Miskovska 5 Jana Obertova Patrik Palacka Rejlekova Sycova-Mila Silvia Cingelova Stanislav Spanik 5, 6 Jozef Mardiak Miroslav # Mego 4, Department of Genetics Cancer Research Institute, Biomedical Center, Slovak Academy Sciences, Bratislava, Slovakia Translational Unit, Faculty Medicine, Comenius University, National 3 2nd Oncology, University and 1st...

10.18632/oncotarget.12515 article EN Oncotarget 2016-10-07

e16523 Background: To evaluate the prognostic value of index combining hemoglobin and albumin levels with lymphocyte platelet counts (HALP) in patients metastatic clear-cell RCC treated nivolumab. Methods: We enrolled 149 subjects (38 females), median age 62 years, nivolumab 240 mg biweekly or 480 each 28 days following progression on at least one TKI from 2016 to 2024. The study population was dichotomized based HALP (24.12), which calculated as (g/L) x absolute number lymphocytes /...

10.1200/jco.2024.42.16_suppl.e16523 article EN Journal of Clinical Oncology 2024-06-01

Background/Aim: Systemic immune-inflammation index (SII) predicts survival of patients with various malignancies. This study explored the prognostic value SII in metastatic urothelial carcinoma (MUC) subjects. Patients and Methods: We evaluated 181 consecutive MUC treated first-line platinum-based therapy. Karnofsky performance status <80% visceral metastasis were present 18.2% 46.4% patients, respectively. was based on platelet × neutrophil/lymphocyte counts. Study population...

10.21873/anticanres.15391 article EN Anticancer Research 2021-11-01

Survivors of testicular germ cell tumors (GCT) may suffer from late cognitive impairment. We hypothesized that disruption intestinal barrier during chemotherapy and/or radiotherapy be a contributing factor dysfunction within the gut-blood-brain axis. GCT survivors (N = 142) National Cancer Institute Slovakia completed Functional Assessment Therapy Cognitive Function questionnaires their annual follow-up visit at 9-year median (range 4-32). Biomarkers gut microbial translocation and dysbiosis...

10.3389/fonc.2023.1146032 article EN cc-by Frontiers in Oncology 2023-03-21

Early serum tumor marker decline (STMD) during chemotherapy was shown to predict survival in patients with poor prognosis non-seminomatous germ cell tumors (GCT) the first line. The aim of study assess prognostic value STMD relapsed GCT;s patients. From January 1995 December 2007, all treated for GCT s salvage therapy at National Cancer Institute Slovakia were identified from registry database and screened retrospectively AFP betaHCG level time relapse. rate calculated each patient an...

10.4149/neo_2009_05_398 article EN Neoplasma 2009-01-01

e16042 Background: Systemic immune-inflammation index (SII) and programmed death-ligand 1 (PD-L1) are prognostic in various types of malignancies. Recently we have shown a value PD-L1 expression on tumor cells infiltrating lymphocytes (TILs) testicular germ cell tumors (GCT). This study aimed to evaluate role SII GCT population patients expressing TILs. Methods: was calculated using platelet (P), neutrophil (N) lymphocyte (L) counts measured prior chemotherapy (SII = P x N/L). our discovery...

10.1200/jco.2017.35.15_suppl.e16042 article EN Journal of Clinical Oncology 2017-05-20
Coming Soon ...